111 related articles for article (PubMed ID: 19822850)
1. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.
Zahn G; Vossmeyer D; Stragies R; Wills M; Wong CG; Löffler KU; Adamis AP; Knolle J
Arch Ophthalmol; 2009 Oct; 127(10):1329-35. PubMed ID: 19822850
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
[TBL] [Abstract][Full Text] [Related]
3. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist.
Umeda N; Kachi S; Akiyama H; Zahn G; Vossmeyer D; Stragies R; Campochiaro PA
Mol Pharmacol; 2006 Jun; 69(6):1820-8. PubMed ID: 16527907
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
[TBL] [Abstract][Full Text] [Related]
5. Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule.
Maier AK; Kociok N; Zahn G; Vossmeyer D; Stragies R; Muether PS; Joussen AM
Curr Eye Res; 2007 Sep; 32(9):801-12. PubMed ID: 17882713
[TBL] [Abstract][Full Text] [Related]
6. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo.
Wang W; Wang F; Lu F; Xu S; Hu W; Huang J; Gu Q; Sun X
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7213-20. PubMed ID: 21813636
[TBL] [Abstract][Full Text] [Related]
7. Optimization of laser-induced choroidal neovascularization in African green monkeys.
Goody RJ; Hu W; Shafiee A; Struharik M; Bartels S; López FJ; Lawrence MS
Exp Eye Res; 2011 Jun; 92(6):464-72. PubMed ID: 21414311
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.
Menguy T; Briaux A; Jeunesse E; Giustiniani J; Calcei A; Guyon T; Mizrahi J; Haegel H; Duong V; Soler V; Brousset P; Bensussan A; Raymond Letron I; Le Bouteiller P
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2687-2698. PubMed ID: 29860455
[TBL] [Abstract][Full Text] [Related]
9. Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration.
Wang WQ; Wang FH; Qin WX; Liu HY; Lu B; Chung C; Zhu J; Gu Q; Shi W; Wen C; Wu F; Zhang K; Sun XD
Mol Pharm; 2016 Sep; 13(9):2881-90. PubMed ID: 27089240
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
11. Repeated retinal photocoagulation in monkeys for the optimization of a laser-induced choroidal neovascularization model.
Lin X; Wang Q; He M
Exp Eye Res; 2019 Jul; 184():1-7. PubMed ID: 30928489
[TBL] [Abstract][Full Text] [Related]
12. Reduction of laser-induced choroidal neovascularization by intravitreal vasohibin-1 in monkey eyes.
Onami H; Nagai N; Machida S; Kumasaka N; Wakusawa R; Ishikawa Y; Sonoda H; Sato Y; Abe T
Retina; 2012 Jun; 32(6):1204-13. PubMed ID: 22366904
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization.
Tolentino MJ; Brucker AJ; Fosnot J; Ying GS; Wu IH; Malik G; Wan S; Reich SJ
Retina; 2004 Feb; 24(1):132-8. PubMed ID: 15076954
[TBL] [Abstract][Full Text] [Related]
14. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
16. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.
Lichtlen P; Lam TT; Nork TM; Streit T; Urech DM
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4738-45. PubMed ID: 20393113
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model.
Olson JL; Courtney RJ; Rouhani B; Mandava N; Dinarello CA
Ocul Immunol Inflamm; 2009; 17(3):195-200. PubMed ID: 19585363
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Murata T; He S; Hangai M; Ishibashi T; Xi XP; Kim S; Hsueh WA; Ryan SJ; Law RE; Hinton DR
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2309-17. PubMed ID: 10892878
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of choroidal neovascularization by intravitreal ketorolac.
Kim SJ; Toma HS
Arch Ophthalmol; 2010 May; 128(5):596-600. PubMed ID: 20457981
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
